Microfluidic Chip Detects Cancer Relapse via White Blood Cell Adhesion

A new, potentially transformative technology in cancer monitoring is emerging from the labs at UNIST (Ulsan National Institute of Science and Technology) in South Korea. Researchers, led by Professor Joo Hun Kang in the Department of Biomedical Engineering, have developed a microfluidic chip capable of tracking cancer relapse by analyzing the adhesion properties of leukocytes – white blood cells – offering a less invasive and potentially more dynamic approach than current methods. This innovation focuses on the body’s immune response to tumors, specifically the increased stickiness of leukocytes triggered by inflammation associated with cancer.

Unlike traditional liquid biopsies, which search for circulating tumor cells themselves, this new method examines how the immune system reacts to the presence of cancer. The findings, recently published in Biosensors and Bioelectronics, suggest a powerful new way to detect minimal residual disease – cancer cells that remain after treatment – and assess how well chemotherapy is working. The study details the development and testing of this microfluidic assay.

How the Microfluidic Chip Works

The core of this technology is a chip containing ultra-thin microchannels. A small blood sample is passed through these channels, which are coated with specialized proteins that mimic the molecules involved in immune cell interactions. When blood flows through, leukocytes that have been activated by tumor-related inflammation adhere to these coated surfaces. An integrated software system then automatically counts the number of adhered leukocytes, providing a quantitative measure of immune activation.

This adhesion isn’t random. Tumor tissue releases inflammatory molecules that activate cell adhesion molecules (CAMs) on leukocytes. These CAMs are crucial for cell-to-cell communication and interaction with the surrounding environment. The more inflammation, the more activated the leukocytes become, and the stronger their adhesion to the chip’s surface.

Preclinical Results and Sensitivity

In laboratory experiments using a mouse model of breast cancer, researchers observed a significant difference in leukocyte adhesion between tumor-bearing mice and healthy controls. Leukocytes from the mice with cancer exhibited up to 40 times more adhesion in the microchannels, directly correlating with tumor activity and inflammation levels. This heightened sensitivity is a key advantage of the new technology.

The system also demonstrated a remarkable ability to track changes in response to treatment. When mice were administered doxorubicin, a common chemotherapy drug, leukocyte adhesion levels decreased, mirroring the observed shrinkage of the tumors. Conversely, ineffective treatments resulted in maintained or increased adhesion, indicating continued tumor activity. This real-time feedback could be invaluable in tailoring treatment plans to individual patients.

Detecting Early Relapse

Perhaps most promisingly, the device was able to detect early signs of metastatic spread – the cancer spreading to other parts of the body – even after the primary tumor had been removed. Leukocyte adhesion levels initially decreased following surgery, but then began to rise again during the early stages of metastasis, potentially allowing for relapse detection before it’s visible through conventional imaging techniques like MRI or CT scans.

Beyond Breast Cancer: The Broader Implications

While the initial research focused on a mouse model of breast cancer, the underlying principle – leveraging the immune response to detect cancer – has broader implications. Professor Kang explains that the approach allows clinicians to monitor relapse and treatment efficacy by analyzing leukocyte adhesion, rather than relying solely on imaging or invasive biopsies. This could lead to more personalized and timely interventions, reducing unnecessary treatments and improving patient outcomes.

The Translational Multiscale Biofluidics Laboratory at UNIST, where Professor Kang leads research, is actively developing biomedical devices aimed at early disease diagnosis and new therapeutic strategies. Their work focuses on understanding the complex behavior of biological fluids and translating that knowledge into practical clinical applications.

What This Means for Cancer Monitoring

Current cancer monitoring often relies on a combination of imaging techniques and, increasingly, liquid biopsies. Imaging, while valuable, can miss small clusters of cancer cells or early signs of relapse. Liquid biopsies, which analyze circulating tumor cells or DNA in the bloodstream, are promising but can be expensive and may not always be sensitive enough to detect minimal residual disease. This new microfluidic chip offers a potentially cost-effective and dynamic complement to these existing methods.

The minimally invasive nature of the test – requiring only a small blood sample – is another significant advantage. It avoids the risks and discomfort associated with more invasive procedures like tissue biopsies. The real-time nature of the analysis provides rapid feedback, allowing clinicians to adjust treatment plans quickly if necessary.

Looking Ahead: Clinical Trials and Further Research

The next step is to validate these findings in larger clinical trials involving human patients. Researchers will require to determine the optimal parameters for the assay, such as the specific proteins used to coat the microchannels and the threshold for detecting significant changes in leukocyte adhesion. They will also need to assess the performance of the chip in different types of cancer and at various stages of the disease.

Further research will also focus on identifying specific biomarkers – measurable indicators of a biological state – that can predict which patients are most likely to benefit from this new technology. Understanding the nuances of the immune response in different individuals will be crucial for maximizing its clinical utility. The team at UNIST is also exploring the potential of combining this microfluidic chip with other diagnostic tools to create a more comprehensive cancer monitoring platform.

This technology represents a significant step forward in the ongoing effort to improve cancer diagnosis and treatment. By harnessing the power of the immune system, researchers are opening up new avenues for early detection, personalized medicine, and better outcomes for patients.

For more information on cancer research and treatment options, consult with a qualified healthcare professional and refer to resources from organizations like the National Cancer Institute.